ClinicalTrials.gg
Active, not recruitingNCT06534450Updated Aug 2, 2024

The Effects Of Therapeutic Plasma Exchange (TPE) On Age Related Biomarkers And Epigenetics

A Phase 3 interventional study of Sham and Therapeutic Plasma Exchange in Aging, sponsored by Dobri Kiprov. Active, not recruiting at 1 site in United States. Open to participants aged 50 Years to 95 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-02.

Sponsored by Dobri Kiprov · Phase 3, Interventional, and Other

From the registry’s dates

  • Registered 1 year 10 months after the study started (first participant enrolled Sep 2022, registered Jul 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
50 Years to 95 Years
Sex
All
01

Study summary

The goal of this clinical trial is to assure the safety of long term therapeutic plasma exchange (TPE) with and without Intravenous Immunoglobulin (IVIG) and its effects on biomarkers and epigenetic biologic clocks in forty individuals. The main question is to assure the safety from long term TPE using changes in clinical and laboratory outcomes and also evaluating changes on additional blood biomarkers and epigenetic clocks during and after TPE treatment. Researchers will compare the TPE treatment group to the Sham treatment group to identify changes due to TPE. Participants will receive six TPE or Sham treatments over one of two treatment schedules and may receive IVIG with treatment.

02

Conditions studied

  • Aging

Keywords

  • Therapeutic Plasma Exchange
03

In context

Lead sponsor

This is the only study on the registry with Dobri Kiprov as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years to 95 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects over 50 years of age with or without chronic inflammatory condition

Exclusion criteria

Exclusion Criteria:

  • Poor peripheral vascular access
  • Diagnosis of active
  • Late-stage Alzheimer's disease Any medical condition which may deteriorate because of plasma exchange procedures. These include, but are not limited to, symptomatic coronary artery disease, congestive heart failure and restrictive pulmonary disease (). The investigators reserve the right to exclude anyone they feel may be harmed in any way by participating in the trial.
  • Presence of active infection
  • Alcohol or drug dependency
  • Psychiatric disorder that will interfere with participation in the study (e.g., schizophrenia, bipolar disorder)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 3
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
40 participants (actual)

Study arms

  • Active comparator
    TPE Monthly

    will receive 6 monthly TPE procedures (TOTAL 6 treatments)

    Device: Therapeutic Plasma Exchange

  • Active comparator
    TPE Bimonthly

    will receive 2 TPE procedures in one week. The same treatment will be repeated on a monthly basis two more times (Two treatments per month for three months to total 6 treatments)

    Device: Therapeutic Plasma Exchange

  • Active comparator
    TPE Bimonthly with IVIG

    will receive 2 TPE procedures followed by 2 gm of IVIG in one week. The same treatment will be repeated on a monthly basis twice more. (Two TPE procedures per month for three months - total of 6 treatments)

    Device: Therapeutic Plasma Exchange · Drug: IVIG

  • Sham comparator
    Sham

    Sham TPE PROCEDURE once a month for 6 months (total of 6 treatments)

    Device: Sham

Interventions

  • DeviceSham

    The patient's blood will not circulate through the apheresis machine. The patient will receive approximately 250 cc of normal saline during each sham pheresis procedure.

  • DeviceTherapeutic Plasma Exchange

    Blood is withdrawn from a peripheral or central vein into the blood cell separator which separates the whole blood into plasma and cell components. The plasma is removed and the blood cells are returned to the patient along with replacement fluids, most commonly 5% human albumin in normal saline.

  • DrugIVIG

    Intravenous Immunoglobulin

06

What researchers measure

Primary outcomes

  1. Adverse events and unanticipated events total for TPE safety

    The primary objective is to assure the safety of long term TPE

    Time frame: through study completion, an average of 1 year

  2. Rate of change to blood epigenetic clock from TPE

    The objective is to compare the rate of change to the blood epigenetic clock from TPE.

    Time frame: through study completion, an average of 1 year

Secondary outcomes

  1. Change in hand grip strength

    The objective is to compare changes in hand grip strength from TPE

    Time frame: after study completion, an average of 2 years

  2. Change in time up and go test

    The objective is to compare changes in the time up and go test from TPE

    Time frame: after study completion, an average of 2 years

  3. Change in balance time

    The objective is to compare changes in balance time from TPE

    Time frame: after study completion, an average of 2 years

  4. Change in short-form health survey score

    The objective is to compare changes in short-form health survey scores from TPE, with higher scores being better

    Time frame: after study completion, an average of 2 years

07

Study locations

1 site
  • Global Apheresis
    Mill Valley, California 94941, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2022 to primary completion in Nov 2023, 14 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2024
First posted
Aug 2, 2024
StartActual
Sep 12, 2022
Primary completionActual
Nov 30, 2023
CompletionEst.
Aug 2025
Last update
Aug 2, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 2, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06534450
Lead sponsor
Dobri Kiprov
Collaborators
CIRCULATE, Inc.
Responsible party
Dobri Kiprov (Chief Medical Officer, Global Apheresis, Inc.) — Sponsor-investigator
First posted
Aug 2, 2024
Start date
Sep 12, 2022
Primary completion
Nov 30, 2023
Completion
Aug 2025 (estimated)
Last update
Aug 2, 2024

Study contacts

Dobri Kiprov, MD
principal investigator · Global Apheresis

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Immunoglobulins, Intravenous

Start the discussion